Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

An embodiment of a CBD or other cannabinoid or terpene or lipid-soluble Nano-Emulsion material and the process comprises a formulation comprising at least a lecithin or mixed lecithin, one or more carrier oils, and a Vitamin E TPGS from a sunflower version and a soy version or Polysorbate 80, 60 or 65. Among either version, the versions may further comprise mixed tocopherols and still further comprise at least one of; an LCT oil, an olive oil, and coconut oil. Any one of the versions may further comprise at least one of; sodium benzoate, potassium sorbate, and sorbic acid, and even yet further comprise purified water. Some embodiments may comprise a Vitamin E acetate or beeswax.

An embodiment of a CBD or other cannabinoid or terpene or lipid-soluble Nano-Emulsion material and the process comprises a formulation comprising at least a lecithin or mixed lecithin, one or more carrier oils, and a Vitamin E TPGS from a sunflower version and a soy version or Polysorbate 80, 60 or 65. Among either version, the versions may further comprise mixed tocopherols and still further comprise at least one of; an LCT oil, an olive oil, and coconut oil. Any one of the versions may further comprise at least one of; sodium benzoate, potassium sorbate, and sorbic acid, and even yet further comprise purified water. Some embodiments may comprise a Vitamin E acetate or beeswax.

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas.

##STR00001## wherein A is —(CH2).sub.a—CH═CH—(CH 2).sub.5-a—H where a is from 0 to 5, —(CH2).sub.b—CH═CH—(CH 2).sub.6-b—H where b is from 0 to 6, —(CH2).sub.c—CH═CH—(CH 2).sub.7-c—H where c is from 0 to 7, —(CH2).sub.d—CH═CH—(CH 2).sub.8-d—H where d is from 0 to 8, or —CH2).sub.e—CH═CH—(CH 2).sub.9-d—H where d is from 0 to 9; B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas.

##STR00001## wherein A is —(CH2).sub.a—CH═CH—(CH 2).sub.5-a—H where a is from 0 to 5, —(CH2).sub.b—CH═CH—(CH 2).sub.6-b—H where b is from 0 to 6, —(CH2).sub.c—CH═CH—(CH 2).sub.7-c—H where c is from 0 to 7, —(CH2).sub.d—CH═CH—(CH 2).sub.8-d—H where d is from 0 to 8, or —CH2).sub.e—CH═CH—(CH 2).sub.9-d—H where d is from 0 to 9; B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Here is presented a novel formulation of a topical treatment containing cannabidiol (CBD), as well as shea butter, cocoa butter coconut oil, aloe vera, body butter, lavender, lemongrass and tangerine. Such formulation may be applied to the skin in a variety of applications. The formulations are made with nearly no THC. Formulations include massage oil, pain relief cream, gardener's relief cream, warming cream, hand and body lotion grip, massage lotion glide and a gardener's relief oil.

Here is presented a novel formulation of a topical treatment containing cannabidiol (CBD), as well as shea butter, cocoa butter coconut oil, aloe vera, body butter, lavender, lemongrass and tangerine. Such formulation may be applied to the skin in a variety of applications. The formulations are made with nearly no THC. Formulations include massage oil, pain relief cream, gardener's relief cream, warming cream, hand and body lotion grip, massage lotion glide and a gardener's relief oil.